Every material Form 8-K Maze Therapeutics, Inc. has filed with the SEC since August 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Maze Therapeutics entered into an exchange agreement on October 15, 2026, with four Frazier Life Sciences funds. Maze exchanged 2,776,007 shares of common stock held by the funds for pre-funded warrants to buy the same number of shares, at an exercise price of $0.001 per share. The filing says the exchange does not change the total count of shares outstanding in the way a new issuance would, but it does create warrants that could later be converted into common stock.
Exchange agreement dated October 15, 2026, with Frazier Life Sciences Public Fund, L.P. and affiliated Frazier funds
2,776,007 shares of common stock exchanged for pre-funded warrants with an exercise price of $0.001 per share
Outstanding common stock was 53,931,889 shares as of October 16, 2026, after giving effect to the exchange
Warrants cannot be exercised if the holder would own more than 9.99% of outstanding common stock, subject to certain exceptions
Maze Therapeutics named two new non-employee directors, Paula Johnson and Sophie Kornowski, effective August 13, 2026, and announced the appointments in a press release that day. The Board also reassigned two existing directors to different classes so that each class has roughly one-third of the Board, as its certificate of incorporation contemplates.
Paula A. Johnson, M.D., M.P.H., joined as a Class III director with a term expiring at the 2028 annual meeting and was added to the nominating and corporate governance committee.
Sophie Kornowski, Pharm.D., joined as a Class I director with a term expiring at the 2029 annual meeting and was added to the audit and compensation committees.
Each new director receives a pro rata share of the $40,000 annual cash retainer and an option to purchase 36,000 shares of common stock, vesting monthly from the appointment date.
Nancy C. Andrews and Hervé Hoppenot resigned and were immediately reappointed to Class II and Class III, respectively.
Maze Therapeutics reported second-quarter 2026 results with a net loss of $44.7 million, or $0.76 per share, up from $33.7 million, or $0.77 per share, a year earlier. The company recognized $20.0 million in license revenue for the first half of 2026, tied to a first-quarter milestone under its Shionogi license, and ended June 30 with $494.9 million in cash, cash equivalents and marketable securities, which it expects will fund operations into 2029.
Q2 2026 net loss was $44.7 million ($0.76 per share), compared with $33.7 million ($0.77 per share) in Q2 2025; no license revenue was recognized in either quarter.
Six-month 2026 net loss was $68.9 million ($1.22 per share), compared with $66.5 million ($1.83 per share) in 2025, including $20.0 million of license revenue from a Shionogi milestone.
Q2 R&D expenses rose to $34.9 million from $28.1 million, and G&A expenses rose to $13.1 million from $8.4 million.
Cash position was $494.9 million at June 30, 2026, up from $360.0 million at December 31, 2025, following an April 2026 offering with gross proceeds of about $150 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Maze Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →